Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04176120 · ClinicalTrials.gov registry record · Phase 3

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)

A Phase 3 study, sponsored by BioTissue Holdings.

Completed
Registry status
Phase 3
Development phase
220
Enrollment target

NCT04176120: Completed Phase 3 study, sponsored by BioTissue Holdings.

NCT04176120 is a Phase 3 study that has completed, run by BioTissue Holdings. The registered enrollment target is 220 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04176120, a Phase 3 study, has completed, sponsored by BioTissue Holdings.

COMPLETED
Registry status
Phase 3
Development phase
220 participants
Enrollment target

Study Summary

It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, will result in a higher rate of wounds showing complete healing within 26 weeks of initiating therapy, compared with standard care alone. This confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.

Primary Outcome

Time from baseline to initial observation of healing, where healing has been confirmed at two consecutive visits each two weeks apart.

Interventions

  • OTHER Standard Care
  • BIOLOGICAL TTAX01

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2020-07-01
Est. Completion 2024-06-12
Phase Phase 3
BioTissue Holdings

13 total trials

What the finished NCT04176120 record still lists

NCT04176120 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (72% lower).

The record links to 0 conditions, and to 2 interventions - of which Standard Care is the first listed.

NCT04176120 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04176120 about?

NCT04176120 is a clinical study titled "Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU)". It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, will result in a higher rate of wounds showing complete healing ...

What is the current status of trial NCT04176120?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2020-07-01. Estimated completion is 2024-06-12.

What interventions are being tested in trial NCT04176120?

The interventions under investigation include: Standard Care (OTHER), TTAX01 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04176120?

This trial is sponsored by BioTissue Holdings, which has 13 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04176120's enrollment target sits among peer trials

220 1318th of 2000 higher than 672 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04176120, the US trial registry maintained by the National Library of Medicine. NCT04176120 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.